[1]李春华,赵 年,陈 武.重组葡激酶-水蛭素融合蛋白在体外循环抗凝溶栓中的应用比较[J].现代检验医学杂志,2015,30(02):19-22,26.[doi:10.3969/j.issn.1671-7414.2015.02.006]
　LI Chun-hua,ZHAO Nian,CHEN Wu.Applying Comparative of Anticoagulant and Thrombolytic Sak-Hirudin Fusion Protein Used in Cardiopulmonary Bypass[J].Journal of Modern Laboratory Medicine,2015,30(02):19-22,26.[doi:10.3969/j.issn.1671-7414.2015.02.006]
点击复制

重组葡激酶-水蛭素融合蛋白在体外循环抗凝溶栓中的应用比较()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年02期
页码:
19-22,26
栏目:
论著
出版日期:
2015-03-20

文章信息/Info

Title:
Applying Comparative of Anticoagulant and Thrombolytic Sak-Hirudin Fusion Protein Used in Cardiopulmonary Bypass
作者:
李春华1; 赵 年1; 陈 武2
1.湖北医药学院附属东风医院影像科,湖北十堰 442000; 2.湖北医药学院,湖北十堰 442000
Author(s):
LI Chun-hua1; ZHAO Nian1; CHEN Wu2
1.Department of Screenage, Affiliated Dongfeng Hospital of Hubei Medical College,Hubei Shiyan 442000,China; 2.Hubei Medical College,Hubei Shiyan 442000,China
关键词:
重组葡激酶-水蛭素融合蛋白;  体外循环;  细胞相容性;  溶血
分类号:
R446.1
DOI:
10.3969/j.issn.1671-7414.2015.02.006
文献标志码:
A
摘要:
目的 探讨与比较抗凝溶栓重组葡激酶-水蛭素融合蛋白在体外循环中的应用优势。方法 2013年2月～2014年7月,选择镍钛合金片分成未包被组(A组)、基础包被组(壳聚糖,B组)、壳聚糖/葡激酶(C组),壳聚糖/水蛭素(D组)、壳聚糖/重组葡激酶-水蛭素融合蛋白(E组),纳入新鲜全人血中进行溶血实验,计算溶血率与血细胞状况。同时健康新生儿脐静脉内皮细胞植入各组别的镍钛合金片,进行细胞相容性实验。结果 5组样品溶血率在1.5%左右,5组的红细胞、白细胞和血小板数量均在正常范围内,各组比较差异均无统计学意义(P<0.05)。E组的增殖程度与黏附程度都明显低于其他4组,对比差异明显(P<0.05); A组与B组的相关比较差异无统计学意义(P>0.05)。随机双盲法细胞计数结果示C,D与E组与A,B组比较差异有统计学显著性意义(P<0.05),同时E组与C,D组对比差异也有统计学意义(P<0.05)。结论 相对于葡激酶与水蛭素的单独应用,重组葡激酶-水蛭素融合蛋白在体外循环中的应用能发挥更强的抗凝、抗血栓作用,安全性好,从而确保心血管疾病介入治疗的有效性。
Abstract:
Objective To investigate the applying comparative values of anticoagulant and thrombolytic Sak - hirudin fusion protein used in cardiopulmonary bypass.Methods From february 2013 toJuly 2014,selected nitinol sheet into uncoated group(group A),base coated group(chitosan,group B),chitosan / Sak group(group C),chitosan/hirudin group(group D),chitosan/Sak-hirudin fusion proteingroup(group E),there were included in the fresh round of blood hemolysis,theblood cell hemolysis rates were calculated.Meanwhile used the healthy newbornsumbilical vein endothelial cells were added into various categories nitinol sheet for cell compatibility testing.Results The samples hemolysis rates in the 5 groups were around 1.5% and the RBC,WBC and PLT countscompared in the 5 groups were showed no differences(P<0.05).The extent ofproliferation and adhesion in the group E were significantly lower than the other four groups,compared to significant differences(P<0.05).There were nodifferences to compare group A and group B(P>0.05).Randomized double-blind cell count result shows that the group C,D and E compared to the group A,Bwere more significant differences(P<0.05),at the same time,the group Ecompared to the group C,D differences were statistically significant(P<0.05).Conclusion Compared to Staphylokinase and hirudinalone,Sak-hirudin fusion protein used in cardiopulmonary bypass can play stronger anticoagulant and antithrombotic effects,its safety and ensures the effectiveness that interventional treatment of cardiovascular disease.

参考文献/References:

[1] 钱方毅.新型口服抗凝剂临床应用的进展[J].中国循环杂志,2012,27(4):246-250. Qian FY.Progress novel oral anticoagulant in clinical application[J].Chinese Circulation Journal,2012,27(4):246-250.
[2] 谢晓林,林 玎,马丽萍,等.脉血康胶囊预防非瓣膜病性房颤患者血栓栓塞56例[J].浙江中西医结合杂志,2012,22(7):521-522. Xie XL,Lin D,Ma LP,et al.Maixuekang capsules with non-valvularatrial fibrillation prevention of thromboembolic disease,56 cases[J].Zhejiang Journal Integrated Traditional Chinese and Western Medicine,2012,22(7):521-522.
[3] Pino CJ, Lou L, Smith PL,et al.A selective cytopheretic inhibitory device for use during cardiopulmonary bypass surgery[J].Perfusion,2012,27(4):311-319.
[4] 刘 浪,陈凯明,赖锋华,等.室间隔缺损介入封堵326例经验总结及随访分析[J].岭南心血管病杂志,2013,19(5):576-579. Liu L,Chen KM,Lai FH,et al.Transcatheter closure of ventricularseptal defects occlucler in 326 cases and follow-up analysis[J].South ChinaJournal of Cardiovascular Disease,2013,19(5):576-579.
[5] Wang J,Ma HP,Zheng H.Blood loss after cardiopulmonary bypass,standardvs titrated protamine:a meta-analysis[J].Neth J Med,2013,71(3):123-127.
[6] 刘轶华,穆晓燕,陈保红.水蛭活血成分研究及临床应用[J].中国现代药物应用,2013,7(11):192-193. Liu YH,Mu XY,Chen BH.Leeches promoting blood components and clinical application[J].Chinese Journal Modern Drug Application,2013,7(11):192-193.
[7] 綦欣竹,闵 苏,魏 珂,等.体外循环对兔胰岛细胞胰岛素信号转导通路的影响[J].中华实验外科杂志,2013,30(1):42-44. Qi XZ,Min S,Wei K,et al.Effects of cardiopulmonary bypass on insulin signal transduction pathway of islet cells rabbits[J].Chinese Journal ofExperimental Surgery,2013,30(1):42-44.
[8] Noui N,Zogheib E,Walczak K,et al.Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device[J].Perfusion,2012,27(3):214-220.
[9] 黄 晶,肖颖彬.体外循环冠脉旁路术和双瓣替换术围术期血浆循环DNA变化及意义[J].第三军医大学学报,2013,35(12):1284-1287.

备注/Memo

备注/Memo:
基金项目:湖北省教育厅课题:抗凝溶栓Hir-RGD-hPLMsp融合蛋白的构建、表达和活性研究,编号:B2013105。 作者简介:李春华(1962-),男,本科,主治医师,研究方向:介入治疗,Tel:13972468887,0719-8272421,E-mail:lich@163.com。
更新日期/Last Update: 2015-03-20